Home – CDMO Solutions | Viral Vectors | Adenovirus
Adenovirus manufacturing expertise proven at scale
OXB is an experienced partner for adenovirus development and manufacturing, most famously demonstrated during the COVID-19 pandemic, when OXB manufactured over 100 million doses of the Oxford–AstraZeneca COVID-19 vaccine. As a quality and innovation-led CDMO, OXB now offers custom adenovirus development as well as tech transfer-in to its clients.
OXB’s adenovirus track record
0
millionCOVID-19 vaccine doses manufactured
0E17
vg/mLAt 1,000L scale
0
monthsTo GMP release
Adenovirus technology and expertise
At OXB, our expertise spans chimpanzee adenovirus (ChAdOx1) and other adenoviral platforms, with capabilities ranging from cell line and process development through GMP production, analytics, fill/finish, and regulatory support. Our processes are built on deep in-house knowledge of vector biology and industrial bioprocessing, enabling rapid, reliable, and scalable production.
Why choose OXB as your adenovirus CDMO?
Experienced partner for adenovirus development and manufacturing
Proven global delivery
OXB has manufactured adenoviral vectors at a scale few others can match, contributing to millions of doses supplied worldwide.
Flexible end-to-end CDMO model
Streamlined development through proven platform processes minimizes risk, accelerates timelines, and cuts expenses.
Advanced GMP infrastructure
OXB has GMP facilities in the UK, Europe and USA to meet the geographical needs of our clients and ensure they benefit from cutting-edge technology and secure global supply chains.
Ways to work with us
There are multiple ways in which pharma, biotechs and start-ups work with us, depending on development phase, scale, and individual IP requirements.
Platform project
For clients that are pre-clinical or early-clinical that wish to reach GMP at an accelerated rate with a proven process.
Custom solution
For clients that are pre-clinical or early-clinical that require flexibility in the manufacture of their drug candidate.
Tech-transfer
For clients in phase I, II, or III that need to transfer their manufacture to a CDMO for scale and/or long-term manufacture.
Frequently asked questions
Yes. OXB provides end-to-end CDMO services, from early process development and analytics through to large-scale GMP manufacturing and commercial supply. We have supported both IND and MAA submissions.
Yes. OXB offers Good Manufacturing Practice (GMP) adenovirus vector production at both clinical and commercial scales, with GMP suits available across the UK, France and the US.
OXB provides a comprehensive analytical suite for adenovirus vectors, including potency, purity, safety, and stability testing. These assays ensure that vectors meet stringent regulatory requirements and provide robust data to support product development and commercial readiness.
OXB combines decades of experience, a global GMP footprint (UK, France & US), regulatory expertise, and proven scalability. Few CDMOs offer the same level of end-to-end adenovirus support alongside expertise in other viral vector platforms, giving clients flexibility and confidence in their long-term partner.